- Ultimovacs ASA – Annual Report 2019
- Ultimovacs ASA – Possible implications of the coronavirus (COVID-19) pandemic
- Ultimovacs ASA: Fourth quarter 2019 result presentation
- Ultimovacs ASA – Ultimovacs appoints Carlos de Sousa as new Chief Executive Officer
- Ultimovacs ASA – Long term results from UV1 clinical study in patients with malignant melanoma
